

Shafiquzzaman Siddiquee
Gan Jet Hong Melvin
Md. Mizanur Rahman *Editors*

Nanotechnology: Applications in Energy, Drug and Food

Nanotechnology: Applications in Energy, Drug and Food

Shafiquzzaman Siddiquee • Gan Jet Hong Melvin
Md. Mizanur Rahman
Editors

Nanotechnology: Applications in Energy, Drug and Food

 Springer

Editors

Shafiquzzaman Siddiquee
Biotechnology Research Institute
Universiti Malaysia Sabah
Kota Kinabalu, Sabah, Malaysia

Gan Jet Hong Melvin
Material and Mineral Research Unit (MMRU)
Faculty of Engineering
Universiti Malaysia Sabah, Jalan UMS
Kota Kinabalu, Sabah, Malaysia

Md. Mizanur Rahman
Faculty of Engineering
Energy Research Unit (ERU)
Universiti Malaysia
Kota Kinabalu, Sabah, Malaysia

ISBN 978-3-319-99601-1 ISBN 978-3-319-99602-8 (eBook)
<https://doi.org/10.1007/978-3-319-99602-8>

Library of Congress Control Number: 2018960259

© Springer Nature Switzerland AG 2019

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Contents

1 Carbon Nanomaterials for Energy Storage Devices	1
Zhipeng Wang and Gan Jet Hong Melvin	
2 Zinc Based Spinel Oxides for Energy Conversion and Storage Applications	31
Faheem K. Butt and Sajid Ur Rehman	
3 Nanotechnology in Renewable Energy: Critical Reviews for Wind Energy	49
W. K. Muzammil, Md. Mizanur Rahman, A. Fazlizan, M. A. Ismail, H. K. Phang, and M. A. Elias	
4 Nanomaterials: Electromagnetic Wave Energy Loss	73
Gan Jet Hong Melvin, Yaofeng Zhu, and Qing-Qing Ni	
5 Emerging Nanotechnology for Third Generation Photovoltaic Cells	99
Biju Mani Rajbongshi and Anil Verma	
6 Nanotechnology: Emerging Opportunities for Fuel Cell Applications	135
Wai Yin Wong and Nabila A. Karim	
7 Nanotechnology-Based Drug Delivery Systems: Past, Present and Future	175
Riana Awang Saman and Mohammad Iqbal	
8 Targeted Therapeutic Nanoparticles for Cancer and Other Human Diseases	187
Rabiatul Basria S. M. N. Mydin, Wan Nordiana Rahman, Rosmazihana Mat Lazim, Amirah Mohd Gazzali, Nur Hazirah Mohd Azlan, and Said Moshawih	

9	Solid Lipid Nanoparticles: A Modern Approach for the Treatment of Neurodegenerative Diseases	209
	Anisha A. D'Souza	
10	Nanoparticles in Nanomedicine Application: Lipid-Based Nanoparticles and Their Safety Concerns	227
	Rabiatul Basria S. M. N. Mydin and Said Moshawih	
11	Nanomaterials in Drug Delivery System	233
	Nur Izzati Mohd Razali, Noor Syazwani Mohd Saufi, Raha Ahmad Raus, Wan Mohd Fazli Wan Nawawi, and Dayang Fredalina Basri	
12	Drug Discovery: A Biodiversity Perspective	249
	Kholis A. Audah	
13	Nano TiO₂ for Biomedical Applications	267
	Khairul Arifah Saharudin, Srimala Sreekantan, Rabiatul Basria S. M. N. Mydin, Siti Nor Qurratu Aini Abd Aziz, and G. Ambarasan Govindasamy	
14	Nanotechnology: Recent Trends in Food Safety, Quality and Market Analysis	283
	Zamri Nurfatihah and Shafiquzzaman Siddiquee	
15	Nanotechnology Applications in Food: Opportunities and Challenges in Food Industry	295
	Afiqah Silon Ummi and Shafiquzzaman Siddiquee	
16	Improvement of Food Packaging Based on Functional Nanomaterial	309
	Bambang Kuswandi and Mehran Moradi	
17	Applications of Polymeric Nanoparticles in Food Sector	345
	Norizah Abdul Rahman	
18	Acetylcholinesterase (AChE) Biosensors for Determination of Carbamate Pesticides	361
	Anwar Samsidar and Shafiquzzaman Siddiquee	
19	Nanosensors Based Detection of Foodborne Pathogens	377
	Mohd Hazani Mat Zaid, Jerro Saikyhan, and Jaafar Abdullah	
20	Electrochemical Methods to Characterize Nanomaterial-Based Transducers for the Development of Noninvasive Glucose Sensors	423
	Nur Alya Batrisya Ismail, Firdaus Abd-Wahab, Nurul Izzati Ramli, Mamoun M. Bader, and Wan Wardatul Amani Wan Salim	

Contributors

Jaafar Abdullah Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Norizah Abdul Rahman Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor Darul Ehsan, Malaysia

Firdaus Abd-Wahab Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University Malaysia, Selangor, Malaysia

Riana Awang Saman Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

Afiqah Silon Ummi Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

Kholis A. Audah Department of Biomedical Engineering and Directorate of Academic Research and Community Services, Swiss German University, Tangerang, Indonesia

Siti Nor Qurratu Aini Abd Aziz School of Materials & Mineral Resources Engineering, Engineering Campus, Universiti Sains Malaysia, Nibong Tebal, Pulau Pinang, Malaysia

Nur Hazirah Mohd Azlan Oncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia

Mamoun M. Bader Department of Chemistry, College of Science and General Studies, Alfaisal University, Riyadh, KSA

Dayang Fredalina Basri Biomedical Science Programme, School of Diagnostic & Applied Health Sciences, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Faheem K. Butt Division of Science and Technology, Department of Physics, University of Education, Lahore, Pakistan

Physik-Department, ECS, Technische Universität München, Garching, Germany

Anisha A. D'Souza Formulation Development Laboratory, Pharmaceutical R&D, Piramal Enterprises Limited, Mumbai, India

M. A. Elias Solar Energy Research Institute (SERI), Universiti Kebangsaan Malaysia, Bangi, Malaysia

A. Fazlizan Solar Energy Research Institute (SERI), Universiti Kebangsaan Malaysia, Bangi, Malaysia

G. Ambarasan Govindasamy School of Materials & Mineral Resources Engineering, Engineering Campus, Universiti Sains Malaysia, Nibong Tebal, Pulau Pinang, Malaysia

Mohammad Iqbal Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

M. A. Ismail Faculty of Engineering, Material and Mineral Research Unit (MMRU), Universiti Malaysia, Kota Kinabalu, Sabah, Malaysia

Nur Alya Batrisya Ismail Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University Malaysia, Selangor, Malaysia

Nabila A. Karim Fuel Cell Institute, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia

Bambang Kuswandi Chemo and Biosensors Group, Faculty of Pharmacy, University of Jember, Jember, East Java, Indonesia

Rosmazihana Mat Lazim Medical Radiation Programme, School of Health Sciences, Universiti Sains Malaysia (Health Campus), Kubang Kerian, Kelantan, Malaysia

Gan Jet Hong Melvin Material and Mineral Research Unit (MMRU), Faculty of Engineering, Universiti Malaysia Sabah, Jalan UMS, Kota Kinabalu, Sabah, Malaysia

Amirah Mohd Gazzali School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Pulau Pinang, Malaysia

Mehran Moradi Department of Food Hygiene and Quality Control, Faculty of Veterinary Medicine, Urmia University, Urmia, West Azarbaijan, Iran

Said Moshawih Jordan Center for Pharmaceutical Research, Amman, Jordan

W. K. Muzammil Faculty of Engineering, Material and Mineral Research Unit (MMRU), Universiti Malaysia, Kota Kinabalu, Sabah, Malaysia

Rabiatul Basria S. M. N. Mydin Oncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia

Wan Mohd Fazli Wan Nawawi Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University of Malaysia, Jalan Gombak, Selangor, Malaysia

Qing-Qing Ni Department of Functional Machinery and Mechanics, Shinshu University, Ueda, Tokida, Japan

Zamri Nurfatihah Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

H. K. Phang Faculty of Engineering, Energy Research Unit (ERU), Universiti Malaysia, Kota Kinabalu, Sabah, Malaysia

Md. Mizanur Rahman Faculty of Engineering, Energy Research Unit (ERU), Universiti Malaysia, Kota Kinabalu, Sabah, Malaysia

Wan Nordiana Rahman Medical Radiation Programme, School of Health Sciences, Universiti Sains Malaysia (Health Campus), Kubang Kerian, Kelantan, Malaysia

Biju Mani Rajbongshi Sustainable Environergy Research Lab (SERL), Department of Chemical Engineering, Indian Institute of Technology Delhi, Delhi, India

Nurul Izzati Ramli Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University Malaysia, Selangor, Malaysia

Raha Ahmad Raus Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University of Malaysia, Jalan Gombak, Selangor, Malaysia

Nur Izzati Mohd Razali Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University of Malaysia, Jalan Gombak, Selangor, Malaysia

Sajid Ur Rehman State Key Laboratory on Integrated Optoelectronics, Institute of Semiconductors, Chinese Academy of Sciences, Beijing, China

Khairul Arifah Saharudin School of Materials & Mineral Resources Engineering, Engineering Campus, Universiti Sains Malaysia, Nibong Tebal, Pulau Pinang, Malaysia

Jerro Saidykhan Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Anwar Samsidar Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

Noor Syazwani Mohd Saufi Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University of Malaysia, Jalan Gombak, Selangor, Malaysia

Shafiquzzaman Siddiquee Biotechnology Research Institute, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

Srimala Sreekantan School of Materials & Mineral Resources Engineering, Engineering Campus, Universiti Sains Malaysia, Nibong Tebal, Pulau Pinang, Malaysia

Anil Verma Sustainable Environergy Research Lab (SERL), Department of Chemical Engineering, Indian Institute of Technology Delhi, Delhi, India

Wan Wardatul Amani Wan Salim Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University Malaysia, Selangor, Malaysia

Zhipeng Wang Institute of Advanced Materials, Jiangxi Normal University, Nanchang, Jiangxi Province, China

Wai Yin Wong Fuel Cell Institute, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia

Mohd Hazani Mat Zaid Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Yaofeng Zhu Key Laboratory of Advanced Textile Materials and Manufacturing Technology, Ministry of Education, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China

About the Editors



Shafiquzzaman Siddiquee is an associate professor in the Biotechnology Research Institute of Universiti Malaysia Sabah (UMS), Malaysia. Dr. Siddiquee obtained his MSc (Molecular Microbiology) and PhD (Bioelectrochemistry) degrees in 2008 and 2010, respectively, from University Putra Malaysia (UPM), Malaysia. In 2011, he received a *Best Post Graduate Award* from UPM for being the most outstanding postgraduate student of the year. In 2014, he was the winner of the *ProSPER.net-Scopus Young Scientist Award* in the category of Sustainable Agriculture. He served as a guest professor at the Institute of Analytical Chemistry, Chemo- and Biosensors of the Regensburg University, Germany, in 2016. Currently he is a head of the UMS Biosensor Research Group. He has involved in varying types of research areas such as chemosensors- or biosensors-based research, management of food wastes, and *Trichoderma* biodiversity and its applications. He has published over 85 refereed journal articles, 4 books, 12 book chapters, and 38 proceeding papers. His findings yielded, so far, 4 patents, 5 invited speaking engagements, and 40 research awards, including notable award of *MOHE entrepreneurial Project Award 2015* and International Conference and Exposition on Inventions by Institutions of Higher Learning 2015 (*PECIPTA 2015*). Dr. Siddiquee has established relevant research group networks both nationally and internationally. In pop culture, Dr. Siddiquee's findings have been broadcast in national (Malaysia) TV stations (TV1, TV2, and TV7) as well as highlighted in various print media.



Gan Jet Hong Melvin received his Ph.D. from Shinshu University, Japan, in 2015. Then, he joined the Institute of Carbon Science and Technology, Japan, for 1 year as a researcher. Now, he is a senior lecturer in Mechanical Engineering Program and a research fellow of Material & Mineral Research Unit at the Faculty of Engineering, Universiti Malaysia Sabah, Malaysia.

His major field is materials science related journals, which includes nanoparticles, hybrid nanomaterials, carbon-based nanomaterials, and composite materials. Some of his previous and current active projects and works are related to polymer-based electroactive actuators, electromagnetic wave absorber, and energy storage devices, which are published in peer-reviewed journals, conference proceedings, and abstracts. He is an active reviewer for several material-related journals and a member of the Board of Engineers, Malaysia.



Md. Mizanur Rahman is working as a senior lecturer in the Mechanical Engineering Program, Faculty of Engineering at Universiti Malaysia Sabah. He has interests in both fundamental and applied aspects of renewable energy technologies, especially in new technology to harvest electricity from solar power and hydro power. Firstly he has started his carrier at the Renewable Energy Technologies in Asia (RETs in Asia) Phase—II Project in 1999 as a Research Engineer under the Department of Mechanical Engineering at Khulna University of Engineering and Technology (KUET) and Asian Institute of Technology (AIT), Bangkok, Thailand, before joining as a Program Support Specialist in 2005 at BRAC, Bangladesh. Dr. Rahman was appointed as an Assistant Manager Technical in 2006 at Rural Power Company Ltd and as a lecturer in 2009 at TAS Institute of Oil and Gas. Finally, he moved to Universiti Malaysia Sabah as senior lecturer in the year 2012. Dr. Rahman has obtained BSc in Engineering (Mechanical), MSc in Environmental Management, and PhD in Mechanical Engineering from BIT Khulna, Bangladesh: jointly from the University of San Francisco, USA, Mahidol University, Bangkok, Thailand, and Universiti Malaysia Sabah in 1998, 2004, and 2012, respectively. He has

published research papers in various journals and national and international conference proceeding. He is a chartered engineer, member of the Institution of Mechanical Engineers (IMechE), UK; fellow of the Institute of Engineers, Bangladesh (IEB); and member of the Bangladesh Society of Mechanical Engineers (BSME), Institute of Material Malaysia (IMM), and the American Society of Mechanical Engineering (ASME).

Chapter 12

Drug Discovery: A Biodiversity Perspective



Kholis A. Audah

12.1 Introduction

12.1.1 Current Health Issues

The complexity of health issues does not significantly reduce by the fast advancement of science and technology and the improvement of human civilization. As a matter of fact, there are more and more diseases, generative or degenerative, infectious or non infectious diseases affecting human's lives. Different factors have contributed to the current health issues which include but not limited to the increasing of human population and transmission, life styles, quality of foods, water and environment and the emerging and re-emerging microbial pathogens.

On the other hand, mankind keeps striving to find drugs not only for fighting the existing diseases but also current emerging ones. Furthermore, antibiotics or drugs that have been used to fight many diseases, constantly loose their effectiveness due to one reason or another. Human are always at a continuous endless battle between finding cure and diseases. Unfortunately, it is so obvious to deny that the speed of drug discovery is at a slower pace than the emerging of diseases. WHO reported that at least 30 new diseases emerged in 20 years period of time (World Health Report 1996). Therefore, it has become a necessity to search for alternatives to find different kinds of drug sources.

K. A. Audah (✉)

Department of Biomedical Engineering and Directorate of Academic Research and Community Services, Swiss German University, Tangerang, Indonesia
e-mail: kholis.audah@sgu.ac.id

12.1.2 *Conceptual Framework of Drug Discovery from Biodiversity*

The concepts of antigen versus antibody, venom versus antidote somehow taught us that Mother Nature provided us the cures for every disease. It is just a matter of how to find the right drug for particular disease which is already available in the nature. By saying so, it is our duty to explore nature, in a responsible manner, to discover drugs for various diseases both existing and ones might emerge in the future. This work should be done collaboratively among individuals with different expertises even among countries that would contribute according their capacities. Some contribute in terms of facilities or expertise, while some others contribute in the form of natural resources. Some countries are simply blessed with very rich biodiversity either on the land (terrestrial) or in the ocean or even both. The most important thing to keep in mind is that all parties should work together for the sake of the betterment of mankind. So that none would think that they are neither more superior nor more important than others.

This chapter briefly described the power of Mother Nature as the abundant sources to find drugs for different kinds of illnesses include the challenges associated with the drug discovery process. Different findings reported by researchers had shown us that most if not all organisms in our planet from simplest form of lives to the most complex ones, from microbes to plants, either on the land or in the ocean possess various types of active compounds that potentially can be used as medicines. We, human being just need to search and discover these virtues provided by God the Almighty and to use them all for the sake of mankind's prosperity in the best possible manners.

Drug discovery through screening process utilizing natural products can become a solution of the slow and expensive drug discovery process using conventional way (Hassig et al. 2014; Li and Vederas 2009; Harvey 2008). In the United States, approximately 50% of drugs approved by Food and Drug Administration (FDA) originated from natural products or their derivatives (Newman and Cragg 2012). The key point of this drug discovery method is that the method requires the availability of a large number of extracts and or compounds for screening purposes. This can be possibly made by exploring the richness of biodiversity. Mother Nature has been known as long as human history as very rich sources for various types of human needs including as medicinal sources.

12.2 Drug Discovery from Natural Products

12.2.1 *The History of Natural Products as Medicinal Sources*

Since centuries ago, human had been relying on natural products, plants in particular, to fulfill their basic needs for food, cloth and housing. Plants can also be used as




Fig. 12.1 Top documented uses of plant species. Graphic: Mongabay; Source: Royal Botanic Gardens Kew: State of the World's Plants 2017

poison on arrow for hunting, halusinogen in ritual, stimulant and medicines (Mann 2000). Plants had become very strong origin in traditional medicine practices in China, India and many other countries including Indonesia (Mittermeier et al. 2005). Long time before bioactive compounds were recognized pharmacologically, plants had been prescribed based on “similarity doctrine”. For example, red color herbs were used to cure diseases related with blood and leaves with liver shape used to cure liver diseases (Sneider 2005). Traditional medicine practices generally use raw or processed materials according to traditions from generation to generation, such as well known boiled tea leaves or other herb formulas.

12.2.2 *The Potential of Biodiversity as Medicinal Sources*

There are about 391,000 species of vascular plants currently known to science, of which about 369,000 species (or 94%) are flowering plants, according to a report by the Royal Botanic Gardens, Kew, in the United Kingdom (Royal Botanical Garden Report 2017). Out of this number, only about 31,000 species have at least one documented use. These include uses for food, medicine, recreation, genes, poisons, animal feed, and building material (Fig. 12.1) (Royal Botanical Garden Report 2017). At least 28,187 plants species are currently recorded as being of medicinal use (State of the World's Plants 2017).

12.2.3 Early Process of Drug Discovery from Natural Products

In later development, herbal medicines had been used in the form of pure bioactive compounds (Salim et al. 2008). Bioactive compounds found in plants are known as secondary metabolites. Secondary metabolites are differentiated into several classes which are alkaloids, terpenoids and phenolics. The discovery of plants secondary metabolites used wider later as medicinal materials either in the form of native compounds or modified ones (Samuelsson 2004). Isolation of bioactive compounds eventually led to discovery of various drugs such as cocaine, codeine, digitoxin and quinine (Newman et al. 2000; Butler 2004; Samuelsson 2004).

Drug discovery processes from plants are involving different area of research and analytical methods. Such processes were initiated by botanist, ethnobotanist, ethnopharmacologist and plant ecologist who collected and identified particular plants. The collected plants were the plants that had been known as medicines or had not been known at all. Phytochemists then do the extraction and do screening by appropriate pharmacological tests and start isolation and characterization of bioactive compounds. Drug discovery processes were then developed to molecular level through determination and implementation of molecular target screening tests which were physiologically appropriate (Balunas and Kinghorn 2005). The combination of different scientific fields mentioned above had become different interdiscipline science which was named as pharmacognosy. During its development, pharmacognosy includes a larger natural product research, bioactive compounds from various sources including bacteria, fungi and marine organisms.

12.2.4 Significant Values of Medicinal Plants in Drug Discovery Process

In last decade, pharmaceutical industries started reducing their drug discovery program from natural products due to vast variety of chemical structure and stereocenter of natural products, so their synthetic form were not economical (Koehn and Carter 2005). Pharmaceutical industries are more interested in modelled molecules, combinatorial and other synthetic chemistry that can produce millions of compounds (Ganesan 2004; Tan 2004). However, utilization of plants or other natural products are still significant parts in drug discovery. Bioactive compounds from natural products contain so many proptotypes of new bioactive compounds which had been proven to be more relevant in relation with new drug discovery process (Koehn and Carter 2005). Drug materials from plants are not only used as new drug materials but also as drug candidates with elevated activity (Kramer and Cohen 2004).

Nowadays, most of pharmaceutical industries' roles related to natural products are taken over by small biotechnology industries which focus on identification of

drug candidate compounds from natural product extracts and develop them to become drugs. Currently, there are many drug candidate compounds originated from plants are under clinical trial phases and introduced by the biotechnology industries, which some of them had become drugs that are commercially available. From the year 1981 to 2002, there were approximately 28% of new chemical compounds isolated from natural products or their derivatives. As many as 20% of them were chemical compounds analogues from natural products. Other researchers reported that in the United States, approximately 50% of drugs approved by Food and Drug Administration (FDA) originated from natural products or their derivatives (Newman and Cragg 2012). Natural products were also as initial point of synthesis of new synthetic compounds (Newman et al. 2003).

The nineteenth century was the beginning of the isolation of a number of other alkaloid compounds from medicinal plants, such as atropine (*Atropa belladonna*), caffeine (*Coffea arabica*), cocaine (*Erythroxylum coca*), efedrine (*Ephedra* sp.), morphine and codein (*Papaver somniferum*), pilocarpine (*Pilocarpus jaborandi* Holmes), physostigmine (*Physostigma venenosum*), quinine (*Cinchona cordifolia mutis ex Humb*), salicine (*Salix* sp.), theobromine (*Theobroma cacao*), theofilline (*Camelia sinensis*), and tubocurarine (*Chondrodendron tomentosum* Ruiz & Pav.). Up to now, isolation and characterization of new bioactive compounds from plants are still ongoing (Sneader 2005).

Artitir is a potential antimalarial compound and is as artemisinin derivative, sesquiterpene lactone isolated from *Artemisia annua* L. (Asteraceae) (Graul 2001). Galantamine, drug for Alzheimer, discovered from lead ethnobotany and isolated for the first time from *Galanthus woronowii* Losinsk (Amaryllidaceae) in Russia in the year 1950 (Pirttila et al. 2004). Nitisinon was new drug from plant that works for rare generative disease, tyrosinemia, showing positive effect in lead structure. Nitisinon was a modification of mesotrione, a compound from *Callistemon citrinus* Stapf. (Myrtaceae) (Frantz and Smith 2003). Tiotropium was recently released in US market for curing chronic obstructive pulmonary disease (COPD). Tiotropium is an inhaled anticholinergic bronchodilator medicine, an atropine derivative isolated from *Atropa Belladonna* L. (Solanaceae) (Frantz 2005). Morphine-6-glucuronid is a morphine metabolite from *Papaver somniferum* L. (Papaveraceae) and was going to be used as morphine substitute due to much smaller side effect (Lotsch and Geisslinger 2001). Vinflunine was modified from Vinblastine from *Catharantus roseus* (L.) G. Don (Apocynaceae) as anticancer (Okouneva et al. 2003). Exatecan was camptothecin analogue from *Camptotheca acuminata* Decne. (Nyssaceae) and was being developed as anticancer (Cragg and Newman 2004). Calanolid was dipyrano-kumarine natural product isolated from *Calophyllum lanigerum* var. *austrororiaceum* (Whitmore) p. F. Stevens (Clusiaceae), Malaysian tropical rain forest tree. Calanolid is an anti HIV drug with a unique work mechanism as reverse transcriptase non-nucleoside inhibitor of type 1 HIV and effective against HIV AZT-resistant strain (Yu et al. 2003).

In addition to direct use as medicinal materials, bioactive compounds from natural products can also be used as drug precursors, prototypes for modification of synthetic compounds or pharmacological markers. Out of 244 identified drug

prototypes, 56 prototypes (23%) of them were secondary metabolites originated from plants (Sneader 2005). Bioactive compounds as drug precursors can be altered into preferred compounds through chemical modification process or fermentation methods (Salim et al. 2008).

By employing advance organic chemistry techniques, pharmacist can make analogue structure of natural products to obtain safer and more potential drugs. New produced compounds sometimes possess new pharmacological properties that can be categorized as derivative compounds. Podofillotoxin, camptothecin and guanidine were some examples of prototypes that their analogue had exactly the same pharmacological properties, while atropine was a prototype that its analogue had different pharmacological properties (Salim et al. 2008).

Bioactive compounds as pharmacological markers help researchers to understand work mechanism of intracellular signal transduction and biological mechanism related with certain diseases, so that better drug design can be achieved. For examples: Genistein, an isoflavone naturally found in soybean (*Glycine max* Merr.) is an inhibitor of various protein tyrosine kinase (PTK), an important enzyme in intracellular signal transduction (Gryniewicz et al. 2000). Different 12,13-diesther forbol also possess capacity to act as tumor promotor or activator protein kinase C (PKC) (Kazanietz 2005).

12.2.5 Challenges in Drug Discovery from Plants

Despite of many success stories of drug discovery from plants, following efforts remain facing many challenges. Pharmacognosist, phytochemist and natural product researchers still have to increase quality and quantity of compounds that enter drug development to be able to compete with chemical drug discovery business. Drug discovery process sometimes need about more than 10 years and spend about more than USD 800 million (Dickson and Gagnon 2004). Many of drug candidates considered failed after spending so much time and money. As a matter of fact, only one in 5000 drug candidate compounds which were entering clinical trials and accepted as drug. The steps mentioned above include identification, optimization and development of drug candidate compounds and then enter clinical trials (Balunas and Kinghorn 2005).

Those facts showed that drug discovery from plants requires longer time and more expensive compared to other drug discovery methods. Thus, many of pharmaceutical industries reduce their natural product research activities (Koehn and Carter 2005). To overcome such issues, it is important to develop a faster, better technology and or strategy, especially in increasing number of plant collection, screening methods, isolation of compounds and development of natural products and their derivatives (Do and Bernard 2004). Other challenge was limited availability of natural product extract, so it is not sufficient for optimization and development of drug candidate compounds. The challenge is also faced at clinical trials phases, so that natural products should be combined with synthetic compounds or chemicals.

Other technique is by developing extract library from natural products that combines natural products features with combinatorial chemistry (Butler 2004). Drug discovery through screening process utilizing natural products can become a solution for the slow and expensive drug discovery process using conventional way (Hassig et al. 2014; Li and Vederas 2009; Harvey 2008). The key point of this drug discovery method is that the method requires the availability of a large number of extracts and or compounds for screening purposes. This can be possibly made by exploring the richness of biodiversity. Mother Nature has been known as long as human history as very rich sources for various types of human needs including medicinal sources.

12.3 Extract Library

Extract library is a collection of extracts containing active compounds from natural products used for screening process of target biology. Although this looks simple, however development of extract library requires good understanding regarding modern paradigm of drug discovery process (Quinn 2012). High quality extract library leads the way in discovery of natural products that can be developed to become drug and early identification point for chemical compound optimization. Current drug discovery process is supported by HTS ability for larger chemical library (up to one million compounds), so that shorten the cycle of drug discovery project. Screening can be performed in 384 or 1536 formats of sample wells with volume of each sample approximately 2–20 μL in each well. Target-based screening and special technology platform is very suitable with current HTS. Unfortunately, this method applies only for pure synthetic compound library and not for crude extracts that contain hundreds of compounds (Quinn 2012).

The concept of extract library was firstly introduced when the High-Throughput Screening (HTS) concept was firstly recognized by pharmaceutical industries (Pereira and Williams 2007). Crude extract library has several benefits, such as cheap and easy preparations, minimum preparation time and possess high diversity level. However, crude extract library has some limitations such as natural physical form is not suitable for automated solution system (too concentrated), minor metabolite cannot be detected, requires longer time and continuous sample supply for isolation and identification of active compounds, the isolated compounds might have been known or non-targeted chemical compounds (Liu 2008).

Natural products pure compounds library was developed to cover the shortage of crude extract library and could become solution for drug discovery research from natural products suitable for high-throughput method (Bindseil et al. 2001). Similar to small synthetic molecules library, pure compounds extract library was designed with strategy adjusted to representative limitation of the desired chemical range (Brenk et al. 2008). Infrastructure and more sophisticated chemical informatics also need to be developed to determine potential extracts containing the desired compounds and to eliminate the undesired compounds. Potential minor components can be detected and included in screening process depend upon final detection or

Table 12.1 Top ten countries with their respective biodiversity in numbers

Country	Birds	Amphibians	Mammals	Reptiles	Fish	Vascular plants
Brazil	1753	1022	648	807	4521	56,215
Colombia	1826	771	442	601	2053	51,220
China	1240	411	551	478	3330	32,200
Indonesia	1615	347	670	728	4682	29,375
Mexico	1081	377	523	916	2602	26,071
South Africa	755	128	297	447	2059	23,420
Venezuela	1364	360	363	405	1709	21,073
United States	844	300	440	530	3067	19,473
India	1180	390	412	689	2465	18,664
Ecuador	1588	539	372	444	1098	19,362

Source: Plant data is from the World Conservation Monitoring Centre of the United Nations Environment Programme (UNEP-WCMC 2004). Species Data. Fish: Fishbase; Birds: Birdlife International; Amphibians: AmphibiaWeb; Mammals: IUCN; Reptiles: the Reptile Database (Butler, 2016)

isolation method used (Roy et al. 2010). Although some pure natural product compounds are already commercially available in affordable price, however majority of compounds need to be isolated individually or obtained from researchers through establishment of consortium. However, the cost, time and related resources with isolation and characterization of single compounds can be reduced.

Final objective of extract library is to obtain resource of different compounds for HTS evaluation (Dandapani et al. 2012). Compounds diversity is strongly correlated with biodiversity. Keep in mind that 17 countries with megabiodiversity in the world (Australia, Brazil, China, Colombia, Democratic Republic of Congo, Ecuador, India, Indonesia, Madagascar, Malaysia, Mexico, Papua New Guinea, Peru, Philippine, South Africa, United States of America and Venezuela) possess more than 70% of the entire biodiversity. Currently, there are approximately 391,000 species of vascular plants currently known to science, of which about 369,000 species (or 94%) are flowering plants, according to a report by the Royal Botanic Gardens, Kew in the United Kingdom (Royal Botanical Garden Report 2017). Out of this number, only about 31,000 species have at least one documented use. These include uses for food, medicine, recreation, genes, poisons, animal feed, and building material (Fig. 12.1) (Royal Botanical Garden Report 2017). In other words, with this large collection of plants available in the world, millions of extracts can be generated. The full list of countries with richest biodiversity in the world is shown in Table 12.1 (Royal Botanical Garden Report 2017).

Indonesia in particular has abundant natural products potential as drug and cosmetics materials both on land and in ocean. According to a report, Indonesia was listed as the big four of the richest country in the world in biodiversity both in the ocean and on the land as shown in Table 12.1 (UNEP 2004). One of the very popular collections of Indonesian herbal is Herbal collection managed by the Main Center for Research and Development of Plant Medicine and Traditional Medicine under the Ministry of Health of Indonesia. This sanctuary is located in Tawangmangu, Karanganyar, Central Java. It is the home of about 2000 Indonesian

medicinal plants. Hundred of thousands of extracts can be generated from this single collection employing various solvents with different polarity.

The basic concept of this extract collection is that there is no single fraction discarded from every step of extraction processes. With the assumption that every extract has its own medicinal potential(s), either the one(s) generated from polar or non polar solvents. These collections can be utilized by different research institutions, universities or pharmaceutical industries for various research and development activities at different stages of research either basic, pre-clinical or clinical studies.

With the assumption, let say about 500 extracts or fractions can be collected from a single plant, there will be around one million extracts or fractions can be collected from 2000 medicinal plants available as in the sanctuary mentioned above (Audah 2015).

12.3.1 Sample Collection

Biota sample collection can be in the forms of bacterial culture, plant collection or marine biota. Some approaches in sample collection can be based upon their uses as traditional medicines or can be performed through random selection. Regardless of the basis of their collection, documentation, for examples place and time, and curation, for examples different parts of plants, are very important aspects for research continuation and downstream activities. Collection that is nationally programmed will ease the related research with conservation and understanding about the genetic resources. Species taxonomy identification is very important to increase the opportunity to discover new species that contain new compound(s) and to avoid the previously known one(s).

The latest biota sample collection strategy requires much less material compared to the requirement of the previous screening process. Development of screening technology, particularly the test with 384 and 1536 wells, approximately 200 mg extract is sufficient for screening several tests in HTS. With the development in spectroscopic structure elucidation, one milligram of compound is already sufficient, either for structure elucidation or biological profile for primary HTS test and some selectivity tests (Quinn 2012).

12.3.2 Extract Collection

Extracts can be collected from the whole biota or particular subsample according to the need for screening. Extraction from the whole biota ensures that all extracts are available for screening, isolation and chemical structure elucidation. However, degradation of compounds can occur to the extracts stored in a longer period of time. The need of time and solvent are larger compared to the extraction procedure of subsample of biota sample. Dried and ground plant sample (simplicia) can maintain

the compound integrity. Moisture should be controlled to prevent sample damage. High moisture increases the chance of fungi and microorganisms to grow. Sample should be stored in each special container and barcoded.

Biota sample can be processed to become several form of extracts suitable for screening such as (1) crude extract which is extraction using organic or mixture of organic solvents; (2) prefractionation crude extract library, which is crude extract that is fractionated using Solid Phase Extraction (SPE) or conventional liquid chromatography technique or combination of both; and (3) pure compound of natural products (Quinn 2012). Furthermore, extract collection requires representative storage room at every extract collection center. Ideally, this type of facility should be located at government institutions, universities or companies appointed as business partners that have the ability to do such big task. Extract collection in smaller numbers can be done in each research center or laboratories. One thing that needs to keep in mind is that all the procedures should be kept uniform (standardized). All these extract collections, either the small ones or the large ones should be well recorded in a database so that the database can be easily managed or organized, utilized and monitored. The database should be accessible to different parties with the permission of the authorized body.

12.3.3 Fractionation and Dereplication Handling

When an extract shows biological activity, fractionation is required to separate groups of compounds which have physical and chemical properties similarity such as solubility and acidity (Hughes et al. 2011). Every fraction is tested and active sample should be repeatedly fractionated to increase purity of the compounds. Test and fractionation process should be continuously performed until pure compounds responsible for particular biological activity obtained. However, repeated fractionation process should be prevented by dereplication process (Katiyar et al. 2012). Dereplication refers to the process of screening active compounds early in the development process to recognize and eliminate those compounds that have been studied in the past, thereby proactively decreasing the number of structures that will need to be fully elucidated and minimizing the amount of time spent on testing (Gaudêncio and Pereira 2015).

The isolated active compound should be purified and its molecular structure should be elucidated. If the active compound was commercially potential, the synthesis of its analog compound and structure-activity relationship (SAR) and quantitative structure-activity relationship (QSAR) studies were required (Guo 2017). However, if the natural source is commercially available to produce adequate active compound, so the synthesis that requires high cost production process and with the complexity of the stereochemistry of active compound can be avoided. For example, anticancer compound Vincristine, Etoposid and Taxol had already been synthesized, these compounds have chiral atom which is more economic when it is produced by extraction process from natural products compared to chemical

synthesis (Demain and Vaishnav 2011). Plant conservation should also be taken into consideration, for example, isolation of Taxol anticancer drug from Yew Pacific plant's bark can cause extinction of the plant. So, nowadays Taxol can be obtained through semisynthetic process from Yew plant's leaf from Europe and America (Juyal et al. 2014).

12.3.4 *Recollection*

Recollection process should consider the conservation concept of species and habitat of collected subjects, because target compound research progressively will require large amount of material, it will give impact to environment. Therefore, it is important that initial collection is well documented. Previous sampling process should be equipped with GPS data, complete documentation and good taxonomy knowledge (WHO 2005).

In conducting biodiscovery research, it should be considered that if recollection of sample in large amount can not be done, target compound should be able to be chemically synthesized. Continuous supply of drug material from plants in adequate amount is very important in fulfilling market demand. Utilization of plant cell culture can be an alternative method for compounds in which their synthetic process is not economical and only available from plant in small amount. Plants accumulate secondary metabolites at certain stages of development. By manipulating environment condition and growth media, desired secondary metabolites can be obtained instead of directly from the entire plant. For example, paclitaxel was successfully produced from fermentation technology of plant cell (Ochoa-Villarreal et al. 2016).

Database formation when the time of sample collection is very important to be adjusted with biodiversity conservation concept and also to trace sample through HTS. Database collection includes taxonomy, time and location, collector either individual or institution and species availability. This will be very helpful in tracing and sample monitoring during research process for accessibility purpose and benefit sharing and recollection. This is also important to identify factors contributing to bioactivity, such as season, location and reproduction cycle stage (Atanasov et al. 2015).

12.3.5 *Screening*

In the past, drug discovery from plant bioactive compounds was a time consuming process. Even just for identifying structure of active compound, it took few weeks even years depend upon the complexity of the compound structure. Nowadays, the speeds of biological assay-based fractionations increase significantly due to the advancement of High Performance Liquid Chromatography (HPLC) tandemed with Mass Spectrometry (MS) or Liquid Chromatography-Mass Spectrometry

(LC-MS), Nuclear Magnetic Resonance (NMR) and High-Throughput Screening with robotic automation. Capillary NMR (cap-NMR) spectroscopy was a breakthrough in characterizing of rare compounds found in organisms (Schroeder dan Gronquist 2006).

Development of HTS technology accelerates extracts screening from plants. Nowadays, biological activity assay is not the limiting factor anymore in drug discovery process. As many as 100,000 samples can be tested in less than a week due to the advancement in data analysis system and the robotic automation usage (Butler 2005). However, plant extract library screening is still facing problem because of the compounds autofluorescence characteristic or the ability of UV light absorption that interferes reading results. To overcome this issue, pre-fractionation of extracts can be applied to reduce some of these problems. In general, HTS can also be equipped with computational screening method to identify and to avoid compounds that can possibly give false positive results (Walters and Namchuk 2003).

Researchers throughout the world are racing in finding new drugs for different illnesses, either the existing or the emerging ones. These include drugs for antibacterial and anticancer. Inappropriate use of antibiotics in some countries had caused antibiotic resistant to some strains, causing serious health problems. Nowadays, many antibiotics are not effective anymore against some infectious diseases caused by bacteria or any other microbes. Therefore, the effort in finding active compounds from natural products either in land or ocean becomes very important. The search also applied to find effective drugs for different types of cancer.

Various methods have been applied to evaluate or screen antibacterial activity in vitro from extracts or pure compounds. The most popular basic method is disk diffusion and broth dilution methods. Disk diffusion method has some advantages compared to other methods such as simplicity, relatively cheaper, and high reliability of the test results on some bacterial species and easiness of test results interpretation (measurement of zone of inhibition) (Balouiri et al. 2016).

In regards with cancer, research on anticancer from plants has become new attraction for researchers in the world. Many of natural products showed pharmacological potential that can be good starting point for discovery of anticancer drug. Vinblastin and Vincristin from plant *Catharantus roseus* has shown their effectiveness to cure cancer in human (Farnsworth and Soejarto 2009). Screening process for natural products with anticancer potential can be conducted using Brine Shrimp Lethality Test (BSLT). In the last 30 years, BSLT are commonly used for toxicity test of various natural products from plants (Mayorga et al. 2010).

BSLT is considered cheap and using less test materials. Since introduced for the first time, this in vivo test was proven to be representative as bioassay guidance for cytotoxic active fractionation and anticancer agent (Ahmed et al. 2010). In addition, other researches suggested that LC₅₀ value obtained from BSLT correlately positive with the results of toxicity oral test in mice (Arslanyolu and Erdemgil 2006).

12.4 Indonesian Biodiversity in a Glimpse

Indonesia is a country that possesses more than 14,000 islands, located between Indian and Pacific Oceans. According to Fauna and Flora International (FFI), Indonesia is home of approximately 11% or more than 30,000 of the world's flowering plants and other biota both in land and marine with significant figures. This makes Indonesia become one of the richest country in the world in biodiversity.

One of potential plants as medicinal and cosmetics sources and widely spread along Indonesian coastline is Mangrove (Fig. 12.2) (UNEP-WCMC). Mangrove dan mangrove associates are very potential plants as medicinal sources (Bandaranayake 2002). Along roughly 90,000 km coastline, Indonesia is home of about 20 family with about hundreds species of mangroves and their associates. Indonesia has the largest mangrove forest or about 23% of total world mangrove forests (Giri et al. 2011). Figure 12.3 showed a mangrove conservation area in eastern coastline of Lampung, Indonesia which was previously an empty land. Today, this conservation area had attracted different species of birds and fishes that migrates from other places.

Since long time ago mangrove trees had been utilized either roots, branches, leaves, flowers and the fruits as food and medicinal sources. Qualitative phytochemistry analysis showed that leaf extract of *Rhizophora stylosa* and *Avicenna marina* contain flavonoid, terpenoid, alkaloid, flavonoid and glycosidic phenolic (Mouafi et al. 2014). Extracts of mangrove fruit also contain some bioactive compounds such as flavonoid, saponin and triterpenoid (Rohaeti et al. 2010).

Mangrove extracts had shown their activity against microbes or pathogen parasites in animals and plants (Batubara et al. 2010; Batubara and Mitsunaga 2013, Audah et al. 2018), including HIV (Rege and Chowdhary 2013) and Hepatitis-B virus (Yi et al. 2015). *Excoecaria agallocha* L can be used to reduce epilepsy,




Fig. 12.2 Hot spots of world's mangrove. Inset is Indonesian mangrove hot spots (UNEP-WCMC)



Fig. 12.3 A mangrove conservation area in Eastern Coastline of Lampung, Indonesia (personal gallery)

conjunctivitis, dermatitis, leprosis, dermatitis, hematuria and toothache (Bandaranayake 2002). Mangrove extracts can also be used as antidiabetes (Gurudeeban et al. 2012), antinociceptive (Islam et al. 2012), antipyretic and antiinflammatory (Safari et al. 2016), anticancer (Singh and Kathiresan 2015), antiulcer (de-Faria et al. 2012).

Hibiscus tiliaceus can act as diuretic and laxative (Tambe and Bhambar 2016). According to Tanvira and Seenivasan (2014), some types of mangrove also can act as antivenom of snakebites. Mangrove extracts can also be used as mosquito's larvicide (Liem et al. 2013).

Up to now, mangrove research in Indonesia and worldwide is still very limited, especially for the purpose of drug discovery. This opens up opportunities for researches to start putting their efforts individually and collaboratively on mangrove research which also applies to mangrove's associates.

12.5 Concluding Remarks

Facing the challenges in discovering new drugs to fight vast diverse diseases, nature has given us abundant resources both in land and marine to search for. It's all up to us, scientists, researchers and all parties to work together to discover alternative for drugs to cure not only existing diseases but also ones that might emerge in the future. It's the time to complement and not to compete each other. People should share what they have for the betterment of mankind and make the world a better place to live for our generations in years to come.

References

- Ahmed Y, Sohrab H, Al-Reza SM, Shahidulla Tareq F, Hasan CM, Sattar MA (2010) Antimicrobial and cytotoxic constituents from leaves of *Sapium baccatum*. *Food Chem Toxicol* 48:549–552
- Arslanyolu M, Erdemgil FZ (2006) Evaluation of the antibacterial activity and toxicity of isolated arctiin from the seeds of *Centaurea sclerolepis*. *J Fac Pharm* 35:103–109
- Atanasov AG et al (2015) Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnol Adv* 33(2015):1582–1614
- Audah KA (2015) Proceedings of the International conference on innovation, entrepreneurship and technology, 25–26 November, BSD City, Indonesia, ISSN: 2477-1538
- Audah KA, Amsyir J, Almasyhur F, Hapsari AM, Sutanto H (2018) Development of extract library from Indonesian biodiversity: exploration of antibacterial activity of mangrove *Bruguiera cylindrica* leaf extracts. *IOP Conf Ser Earth Environ Sci* 130(1):012025
- Balouiri M, Sadiki M, Ibsouda SK (2016) Methods for in vitro evaluating antimicrobial activity: a review. *J Pharm Anal* 6(2):71–79
- Balunas MJ, Kinghorn AD (2005) Drug discovery from medicinal plants. *Life Sci* 78 (2005):431–441
- Bandaranayake WM (2002) Bioactive compounds and chemicals constituents of mangrove plants. *Wet Ecol Manag* 10:421–452
- Batubara I, Mitsunaga T (2013) Use of Indonesian medicinal plant products against acne. *Rev Agric Sci* 1:11–30
- Batubara I, Darusman LK, Mitsunaga T, Rahminiwati M, Djauhari E (2010) Potency of Indonesian medicinal plants as tyrosinase inhibitor and antioxidant agent. *J Biol Sci* 10(2):138144
- Bindseil KU, Jakupovic J, Wolf D, Lavayre J, Leboul J, van der Pyl D (2001) Pure compound libraries: a new perspective for natural product based drug discovery. *Drug Discov Today* 6:840–847
- Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, Wyatt PG (2008) Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. *ChemMedChem* 3(3):435–444
- Butler MS (2004) The role of natural product chemistry in drug discovery. *J Nat Prod* 67 (12):2141–2153
- Butler MS (2005) Natural products to drugs: natural product derived compounds in clinical trials. *Nat Prod Rep* 2005(22):162
- Butler, R.A., 2016. The top 10 most biodiverse countries: What are the world's most biodiverse countries? <https://news.mongabay.com/2016/05/top-10-biodiverse-countries/> Retrieved from internet on April 30, 2018
- Cragg GM, Newman DJ (2004) A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. *J Nat Prod* 67(2):232–244
- Dandapani S, Rosse G, Southall N, Salvino JM, Thomas CJ (2012) Selecting, acquiring, and using small molecule libraries for high-throughput screening. *Curr Protoc Chem Biol* 4:177–191. <https://doi.org/10.1002/9780470559277.ch110252>
- Demain AL, Vaishnav P (2011) Natural products for cancer chemotherapy. *J Microbial Biotechnol* 4(6):687–699
- Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. *Nat Rev Drug Discov* 3(5):417–429
- Do QT, Bernard P (2004) Pharmacognosy and reverse pharmacognosy: a new concept for accelerating natural drug discovery. *IDrugs* 7(11):1017–1027
- de-Faria FM et al (2012) Mechanisms of action underlying the gastric antiulcer activity of the *Rhizophora mangle* L. *J Ethnopharmacol* 139(1):234–243
- Farnsworth NR, Soejarto DD (2009) Global importance of medicinal plants. In: Akerele O, Heywood V, Syngé H (eds) *Conservation of medicinal plants*, 1st edn. Cambridge University Press, Cambridge, pp 25–52

- Frantz S (2005) 2004 approvals: the demise of the blockbuster? *Nat Rev Drug Discov* 4(2):93–94
- Frantz S, Smith A (2003) New drug approvals for 2002. *Nat Rev Drug Discov* 2(2):95–96
- Ganesan A (2004) Natural products as a hunting ground for combinatorial chemistry. *Curr Opin Biotechnol* 15(6):584–590
- Gaudêncio SP, Pereira F (2015) Dereplication: racing to speed up the natural products discovery process. *Nat Prod Rep* 32:779–810. <https://doi.org/10.1039/C4NP00134F>
- Giri C et al (2011) Status and distribution of mangrove forests of the world using earth observation satellite data. *Glob Ecol Biogeogr* 20(1):154–159
- Graul AI (2001) The year's new drugs. *Drug News Perspect* 14(1):12–31
- Grynkiewicz G, Achmatowicz O, Pucko W (2000) Bioactive isoflavone—genistein; synthesis and prospective applications. *Herba Polon* 46:151–160
- Guo Z (2017) The modification of natural products for medical use. *Acta Pharm Sin B* 7(2):119–136
- Gurudeeban S et al (2012) Antidiabetic effect of a black mangrove species *Aegiceras corniculatum* in alloxan-induced diabetic rats. *J Adv Pharm Technol Res* 3(1):52–56
- Harvey AL (2008) Natural products in drug discovery. *Drug Discov Today* 13:894–901
- Hassig CA et al (2014) Ultra-high-throughput screening of natural product extracts to identify proapoptotic inhibitors of Bcl-2 family proteins. *J Biomol Screen* 19(8):1201–1211
- Hughes JP, Rees S, Kalindjian SB, Philpott KL (2011) Principles of early drug discovery. *Br J Pharmacol* 162:1239–1249
- Islam MA et al (2012) Antinociceptive activity of methanolic extract of *Acanthus ilicifolius* Linn leaves. *Turk J Pharm Sci* 9(1):51–60
- Juyal D, Thawani V, Thaledi S, Joshi M (2014) Ethnomedical properties of *Taxus wallichiana* Zucc. (Himalayan Yew). *J Tradit Complement Med* 4(3):159–161
- Katiyar C, Gupta A, Kanjilal S, Katiyar S (2012) Drug discovery from plant sources: an integrated approach. *Ayu* 33(1):10–19
- Kazanietz MG (2005) Targeting protein kinase C and “non-kinase” phorbol ester receptors: emerging concepts and therapeutic implications. *Biochim Biophys Acta* 1754:296
- Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. *Nat Rev Drug Discov* 4(3):206–220
- Kramer R, Cohen D (2004) Functional genomics to new drug targets. *Nat Rev Drug Discov* 3(11):965–972
- Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? *Science* 325(5937):161–165
- Liem AF, Holle E, Gemnafle IY, Wakum DS (2013) Isolasi Senyawa Saponin dari Mangrove Tanjung (*Bruguiera gymnorrhiza*) dan Pemanfaatannya sebagai Pestisida Nabati pada Larva Nyamuk. *Jurnal Biologi Papua* 5(1):29–36
- Liu Z (2008) Preparation of botanical samples for biomedical research. *Endocr Metab Immune Disord Drug Targets* 8(2):112–121
- Lotsch J, Geisslinger G (2001) Morphine-6-glucuronide: an analgesic of the future? *Clin Pharmacokinet* 40(7):485–499
- Mann J (2000) *Murder, magic and medicine*, 2nd edn. Oxford University Press, Oxford
- Mayorga P, Pérez KR, Cruz SM, Cáceres A (2010) Comparison of bioassays using the anostracan crustaceans *Artemia salina* and *Thamnocephalus platyurus* for plant extract toxicity screening. *Rev Bras Farmacogn* 20:897–903
- Mittermeier RA, Gil PR, Hoffman M, Pilgrim J, Brooks T, Mittermeier CG, Lamoreux J, da Fonseca GAB, Seligmann PA, Ford H (2005) Hotspots revisited: earth's biologically richest and most endangered terrestrial ecoregions. Conservation International, New York
- Mouafi FE et al (2014) Phytochemical analysis and antibacterial activity of mangrove leaves (*Avicenna marina* and *Rhizophora stylosa*) against some pathogens. *World Appl Sci J* 29(4):547–554
- Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J Nat Prod* 75(3):311–335

- Newman DJ, Cragg GM, Snader KM (2000) The influence of natural products upon drug discovery. *Nat Prod Rep* 17(3):215–234
- Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981–2002. *J Nat Prod* 66(7):1022–1037
- Ochoa-Villarreal M, Howat S, Hong SM, Jang MO, Jin YW, Lee EK, Loake GJ (2016) Plant cell culture strategies for the production of natural products. *BMB Rep* 49(3):149–158
- Okouneva T, Hill BT, Wilson L, Jordan MA (2003) The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. *Mol Cancer Ther* 2(5):427–436
- Pereira DA, Williams JA (2007) Origin and evolution of high throughput screening. *Br J Pharmacol* 152(1):53–61
- Pirttila T, Wilcock G, Truyen L, Damaraju CV (2004) Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. *Eur J Neurol* 11(11):734–741
- Quinn RJ (2012) Basics and principles for building natural product-based libraries for HTS. In: Haian F (ed) *Chemical genomics*. Cambridge University Press, Cambridge
- Rege AA, Chowdhary AS (2013) Evaluation of mangrove plants as putative HIV-protease inhibitors. *Indian Drugs* 50(7):41
- Rohaeti, E et al. (2010) Potensi Ekstrak Rhizophora sp. Sebagai inhibitor tirosinase. *Prosiding Semnas Sains III*. IPB, Bogor, 13 November, pp 196–201
- Roy A, McDonald PR, Sittampalam S, Chaguturu R (2010) Open access high throughput drug discovery in the public domain: a Mount Everest in the making. *Curr Pharm Biotechnol* 11(7):764–778
- Royal Botanical Garden Report (2017) State of the world's plants. Royal Botanic Gardens, Kew
- Safari VZ et al (2016) Antipyretic, antiinflammatory and antinociceptive activities of aqueous bark extract of *Acacia nilotica* (L.) Delile in albino mice. *J Pain Manag Med* 2:113
- Salim AA et al (2008) Drug discovery from plants. In: Ramawat KG, Mérillon JM (eds) *Bioactive molecules and medicinal plants*. Springer, Berlin. https://doi.org/10.1007/978-3-540-74603-4_1
- Samuelsson G (2004) *Drugs of Natural Origin*, 5th edn. Apotekarsocieteten, Stockholm
- Schroeder FC, Gronquist M (2006) Extending the scope of NMR spectroscopy with microcoil probes. *Angew Chem Int Ed* 45(43):7122–7131
- Singh CR, Kathiresan K (2015) Effect of cigarette smoking on human health and promising remedy by mangroves. *Asian Pacific Journal of Tropical Biomedicine* 5(2):162–167
- Snader W (2005) *Drug discovery: a history*. Wiley, Chichester
- Tambe VD, Bhambar RS (2016) Studies on diuretics and laxative activity of the *Hibiscus tiliaceus* Linn. bark extracts. *Int J PharmTech Res* 9(3):305–310
- Tan DS (2004) Current progress in natural product-like libraries for discovery screening. *Comb Chem High Throughput Screen* 7(7):631–643
- Tanvira P, Seenivasan R (2014) Targeting mangrove species as an alternative for snake bite envenomation therapy with special reference to phospholipase A2 inhibitory activity: a mini review. *Res J Pharm Biol Chem Sci* 5(2):1724–1731
- Walters WP, Namchuk M (2003) Designing screens: how to make your hits a hit. *Nat Rev Drug Discov* 2:259–266
- WHO (2005) WHO guidelines for sampling of pharmaceutical products and related materials. WHO Technical Report Series, No. 929
- World Health Organization (1996) The World health report : 1996 : fighting disease, fostering development / report of the Director-General. Geneva : World Health Organization. <http://www.who.int/iris/handle/10665/36848>
- Yi XX et al (2015) Four new cyclohexylideneacetonitrile derivatives from the hypocotyl of mangrove (*Bruguiera gymnorrhiza*). *Molecules* 20(8):14565–14575
- Yu D, Suzuki M, Xie L, Morris-Natschke SL, Lee KH (2003) Recent progress in the development of coumarin derivatives as potent anti-HIV agents. *Med Res Rev* 23(3):322–345